Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Short-term Investments (2016 - 2018)

Sanofi's Short-term Investments history spans 3 years, with the latest figure at $90.7 million for Q4 2017.

  • For Q4 2017, Short-term Investments rose 170.86% year-over-year to $90.7 million; the TTM value through Dec 2017 reached $90.7 million, up 170.86%, while the annual FY2017 figure was $87.0 million, 153.38% up from the prior year.
  • Short-term Investments for Q4 2017 was $90.7 million at Sanofi, up from $33.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $90.7 million in Q4 2017 and bottomed at $14.2 million in Q4 2015.
  • The 3-year median for Short-term Investments is $33.5 million (2016), against an average of $46.1 million.
  • The largest annual shift saw Short-term Investments surged 134.9% in 2016 before it soared 170.86% in 2017.
  • A 3-year view of Short-term Investments shows it stood at $14.2 million in 2015, then soared by 134.9% to $33.5 million in 2016, then skyrocketed by 170.86% to $90.7 million in 2017.
  • Per Business Quant, the three most recent readings for SNY's Short-term Investments are $90.7 million (Q4 2017), $33.5 million (Q4 2016), and $14.2 million (Q4 2015).